Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

@article{Bokemeyer2011EfficacyAT,
  title={Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.},
  author={Carsten Bokemeyer and Igor Bondarenko and Joerg Thomas Hartmann and Filippo G. de Braud and Gunter Schuch and Angela Zubel and I. Celik and Michael Schlichting and Piotr Koralewski},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2011},
  volume={22 7},
  pages={
          1535-46
        }
}
  • Carsten Bokemeyer, Igor Bondarenko, +6 authors Piotr Koralewski
  • Published in
    Annals of oncology : official…
    2011
  • Medicine
  • BACKGROUND The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS The biomarker analysis was extended through the use of additional DNA samples extracted from stained tissue sections. KRAS and… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 416 CITATIONS, ESTIMATED 57% COVERAGE

    Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers

    VIEW 7 EXCERPTS
    CITES RESULTS & BACKGROUND
    HIGHLY INFLUENCED

    Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies

    VIEW 14 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial

    VIEW 10 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    NRAS und SMAD4 als Biomarker bei fortgeschrittenem Pankreaskarzinom

    VIEW 5 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Prognostic impact of KRAS and BRAF mutations in patients who underwent simultaneous resection for initially resectable colorectal liver metastases.

    VIEW 4 EXCERPTS
    CITES BACKGROUND & RESULTS
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2011
    2020

    CITATION STATISTICS

    • 28 Highly Influenced Citations

    • Averaged 40 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 32 REFERENCES

    Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

    VIEW 7 EXCERPTS

    Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial

    • E Van Cutsem, I Lang, G Folprecht
    • In American Society of Clinical Oncology
    • 2010
    VIEW 6 EXCERPTS
    HIGHLY INFLUENTIAL

    Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

    Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: the effect of infusional 5-FU or capecitabine on the outcomes of the MRC COIN trial in advanced colorectal cancer (ACRC)

    • TS Maughan, R Adams, CG Smith
    • In American Society of Clinical Oncology
    • 2010
    VIEW 1 EXCERPT